Related Experiment Video

Updated: Aug 14, 2026

Cardiac Pressure-Volume Loop Analysis Using Conductance Catheters in Mice
08:15

Cardiac Pressure-Volume Loop Analysis Using Conductance Catheters in Mice

Published on: September 17, 2015

Treatment of moderate or severe arterial hypertension with losartan

A Dimitrova1, M Todorova, K Bianov

  • 1Department of Cardiology, Medical University, Sofia, Bulgaria.

Folia Medica
|April 17, 1999
PubMed

Insights

Losartan, a novel angiotensin II receptor antagonist, significantly reduced systolic and diastolic blood pressure in patients. The study found Cozaar to be well-tolerated with no adverse effects on metabolism or kidney function.

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology

Background:

  • Hypertension remains a significant global health concern.
  • Angiotensin II receptor antagonists represent a novel therapeutic class for managing high blood pressure.
  • Losartan (Cozaar) is the first-in-class angiotensin II receptor antagonist.

Purpose of the Study:

  • To evaluate the efficacy and tolerability of Losartan in hypertensive patients.
  • To assess the impact of Losartan on blood pressure levels.
  • To investigate potential effects on hematopoiesis, metabolism, and renal function.

Main Methods:

  • A study involving fifteen patients with an average age of 48.9 years.
  • Treatment with Losartan (Cozaar).
  • Monitoring of systolic and diastolic blood pressure, hematopoiesis, carbohydrate and lipid metabolism, and renal function.

Main Results:

  • A significant reduction in systolic blood pressure by 15.9%.
  • A considerable decrease in diastolic blood pressure by 20.3%.
  • No significant adverse effects observed on hematopoiesis, carbohydrate and lipid metabolism, or renal function.

Conclusions:

  • Losartan (Cozaar) demonstrates significant antihypertensive efficacy.
  • The drug exhibits good tolerability and a favorable safety profile.
  • Losartan is a promising treatment option for hypertension without negatively impacting key metabolic and renal parameters.

More Related Videos

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension04:37

Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension

Published on: June 6, 2025

Related Concept Videos

Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Aortic Regurgitation III: Medical Management01:25

Aortic Regurgitation III: Medical Management

Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
Hypertension IV: Drug Therapy and Lifestyle Modifications01:28

Hypertension IV: Drug Therapy and Lifestyle Modifications

Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...